Research output per year
Research output per year
Personal profile
Research interests
My research focuses on the identification of tumor specific mutant antigens recognized by the immune system as foreign that serve as the target of a T-cell response against tumors. We take advantage of cancer genomics and bioinformatics techniques to detect tumor-specific mutations that accumulate during transformation and use this information to predict which mutations are potentially antigenic.
Clinical interests
Cancer/tumor immunotherapy
Available to Mentor:
- PhD/MSTP Students
Fingerprint
Dive into the research topics where Jeffrey Ward is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Trends in Stage I Lung Cancer
Singareddy, A., Flanagan, M. E., Samson, P. P., Waqar, S. N., Devarakonda, S., Ward, J., Herzog, B. H., Rohatgi, A., Robinson, C., Gao, F., Govindan, R., Puri, V. & Morgensztern, D., Mar 2023, In: Clinical Lung Cancer. 24, 2, p. 114-119 6 p.Research output: Contribution to journal › Article › peer-review
-
BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
Salmon, A. J., Shavkunov, A. S., Miao, Q., Jarjour, N. N., Keshari, S., Esaulova, E., Williams, C. D., Ward, J. P., Highsmith, A. M., Pineda, J. E., Taneja, R., Chen, K., Edelson, B. T. & Gubin, M. M., May 2022, In: Cancer immunology research. 10, 5, p. 597-611 15 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer
Knapp, B., Mezquita, L., Devarakonda, S., Aldea, M., Waqar, S. N., Pepin, K., Ward, J. P., Botticella, A., Howarth, K., Knape, C., Morris, C., Govindan, R., Besse, B. & Morgensztern, D., Mar 28 2022, In: Frontiers in Oncology. 12, 856132.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
Ward, J. P., Berrien-Elliott, M. M., Gomez, F., Luo, J., Becker-Hapak, M., Cashen, A. F., Wagner-Johnston, N. D., Maddocks, K., Mosior, M., Foster, M., Krysiak, K., Schmidt, A., Skidmore, Z. L., Desai, S., Watkins, M. P., Fischer, A., Griffith, M., Griffith, O. L., Fehniger, T. A. & Bartlett, N. L., Mar 31 2022, In: Blood. 139, 13, p. 1999-2010 12 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors
Herzog, B. H., Waqar, S. N., Devarakonda, S., Ward, J. P., Gao, F., Govindan, R. & Morgensztern, D., Nov 2022, In: Lung Cancer. 173, p. 101-106 6 p.Research output: Contribution to journal › Article › peer-review